vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and TRICO BANCSHARES (TCBK). Click either name above to swap in a different company.
TRICO BANCSHARES is the larger business by last-quarter revenue ($109.4M vs $86.8M, roughly 1.3× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 9.0%). TRICO BANCSHARES produced more free cash flow last quarter ($127.9M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 5.4%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Trico Bancshares is a U.S.-headquartered regional bank holding company operating Tri Counties Bank. It offers a full range of retail and commercial banking services including deposit products, mortgages, small business loans, and wealth management, primarily serving consumers and SMEs in Northern California.
IOVA vs TCBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $109.4M |
| Net Profit | — | $33.6M |
| Gross Margin | 67.4% | — |
| Operating Margin | -84.7% | 42.6% |
| Net Margin | — | 251.6% |
| Revenue YoY | 17.7% | 9.0% |
| Net Profit YoY | — | 15.8% |
| EPS (diluted) | — | $1.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $109.4M | ||
| Q3 25 | $67.5M | $107.6M | ||
| Q2 25 | $60.0M | $103.6M | ||
| Q1 25 | $49.3M | $98.6M | ||
| Q4 24 | $73.7M | $100.4M | ||
| Q3 24 | $58.6M | $99.1M | ||
| Q2 24 | $31.1M | $97.9M | ||
| Q1 24 | $715.0K | $98.5M |
| Q4 25 | — | $33.6M | ||
| Q3 25 | $-91.3M | $34.0M | ||
| Q2 25 | $-111.7M | $27.5M | ||
| Q1 25 | $-116.2M | $26.4M | ||
| Q4 24 | — | $29.0M | ||
| Q3 24 | $-83.5M | $29.1M | ||
| Q2 24 | $-97.1M | $29.0M | ||
| Q1 24 | $-113.0M | $27.7M |
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | — | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -84.7% | 42.6% | ||
| Q3 25 | -140.7% | 43.2% | ||
| Q2 25 | -189.8% | 36.5% | ||
| Q1 25 | -245.8% | 35.8% | ||
| Q4 24 | -117.5% | 38.7% | ||
| Q3 24 | -152.1% | 39.8% | ||
| Q2 24 | -327.6% | 40.0% | ||
| Q1 24 | -16464.6% | 38.3% |
| Q4 25 | — | 251.6% | ||
| Q3 25 | -135.3% | 31.6% | ||
| Q2 25 | -186.2% | 26.6% | ||
| Q1 25 | -235.5% | 26.7% | ||
| Q4 24 | — | 221.4% | ||
| Q3 24 | -142.7% | 29.3% | ||
| Q2 24 | -312.2% | 29.7% | ||
| Q1 24 | -15800.8% | 28.2% |
| Q4 25 | — | $1.02 | ||
| Q3 25 | — | $1.04 | ||
| Q2 25 | $-0.33 | $0.84 | ||
| Q1 25 | $-0.36 | $0.80 | ||
| Q4 24 | $-0.24 | $0.88 | ||
| Q3 24 | $-0.28 | $0.88 | ||
| Q2 24 | $-0.34 | $0.87 | ||
| Q1 24 | $-0.42 | $0.83 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $157.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $1.3B |
| Total Assets | $913.2M | $9.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $157.0M | ||
| Q3 25 | $300.8M | $298.8M | ||
| Q2 25 | $301.2M | $314.3M | ||
| Q1 25 | $359.7M | $308.3M | ||
| Q4 24 | $323.8M | $145.0M | ||
| Q3 24 | $397.5M | $320.1M | ||
| Q2 24 | $412.5M | $206.6M | ||
| Q1 24 | $356.2M | $82.8M |
| Q4 25 | $698.6M | $1.3B | ||
| Q3 25 | $702.3M | $1.3B | ||
| Q2 25 | $698.5M | $1.3B | ||
| Q1 25 | $767.9M | $1.3B | ||
| Q4 24 | $710.4M | $1.2B | ||
| Q3 24 | $773.5M | $1.2B | ||
| Q2 24 | $768.5M | $1.2B | ||
| Q1 24 | $680.0M | $1.2B |
| Q4 25 | $913.2M | $9.8B | ||
| Q3 25 | $904.9M | $9.9B | ||
| Q2 25 | $907.4M | $9.9B | ||
| Q1 25 | $966.7M | $9.8B | ||
| Q4 24 | $910.4M | $9.7B | ||
| Q3 24 | $991.1M | $9.8B | ||
| Q2 24 | $964.3M | $9.7B | ||
| Q1 24 | $869.8M | $9.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $133.3M |
| Free Cash FlowOCF − Capex | $-61.9M | $127.9M |
| FCF MarginFCF / Revenue | -71.3% | 116.9% |
| Capex IntensityCapex / Revenue | 10.7% | 4.9% |
| Cash ConversionOCF / Net Profit | — | 3.96× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $222.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $133.3M | ||
| Q3 25 | $-78.7M | $45.1M | ||
| Q2 25 | $-67.4M | $29.2M | ||
| Q1 25 | $-103.7M | $24.5M | ||
| Q4 24 | $-73.3M | $109.7M | ||
| Q3 24 | $-59.0M | $28.6M | ||
| Q2 24 | $-98.4M | $31.8M | ||
| Q1 24 | $-122.3M | $25.1M |
| Q4 25 | $-61.9M | $127.9M | ||
| Q3 25 | $-89.5M | $43.2M | ||
| Q2 25 | $-74.9M | $28.2M | ||
| Q1 25 | $-109.9M | $22.8M | ||
| Q4 24 | $-77.5M | $105.2M | ||
| Q3 24 | $-61.3M | $27.3M | ||
| Q2 24 | $-98.9M | $30.8M | ||
| Q1 24 | $-126.5M | $24.1M |
| Q4 25 | -71.3% | 116.9% | ||
| Q3 25 | -132.7% | 40.2% | ||
| Q2 25 | -124.9% | 27.2% | ||
| Q1 25 | -222.8% | 23.1% | ||
| Q4 24 | -105.1% | 104.8% | ||
| Q3 24 | -104.6% | 27.6% | ||
| Q2 24 | -317.9% | 31.5% | ||
| Q1 24 | -17685.3% | 24.4% |
| Q4 25 | 10.7% | 4.9% | ||
| Q3 25 | 16.1% | 1.7% | ||
| Q2 25 | 12.4% | 1.0% | ||
| Q1 25 | 12.6% | 1.7% | ||
| Q4 24 | 5.7% | 4.5% | ||
| Q3 24 | 3.9% | 1.3% | ||
| Q2 24 | 1.4% | 1.0% | ||
| Q1 24 | 583.4% | 1.0% |
| Q4 25 | — | 3.96× | ||
| Q3 25 | — | 1.33× | ||
| Q2 25 | — | 1.06× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 3.78× | ||
| Q3 24 | — | 0.98× | ||
| Q2 24 | — | 1.10× | ||
| Q1 24 | — | 0.90× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
TCBK
Segment breakdown not available.
